A Screening Test for in a Large United States Patient Cohort Identifies Broader Risk of Carbamazepine-Induced Adverse Events.

is strongly associated with life-threatening severe skin hypersensitivity reactions in patients treated with carbamazepine (CBZ) and structurally related medications. FDA-approved labeling recommends screening before CBZ therapy in patients of Asian ancestry. In this study, we aimed to (a) identify a direct method for screening , and (b) evaluate prevalence in a large cohort of United States patients.